Observation on the therapeutic effect of butylphthalein combined with edaravone camphor in the treatment of acute cerebral infarction
Objective:To analyze the efficacy of butylphthalide combined with edaravone and right camphanol in the treatment of acute cerebral infarction.Method:Eighty patients with acute cerebral infarction who were diagnosed and treated in our hospital from January 2022 to January 2023 were randomly divided into two groups,with 40 cases in each group.The control group received intravenous infusion of 20 mg of butylphthalide,Bid,and the observation group received continuous treatment for 14 days with edaravone and right camphanol 30 mL Qd,in addition to the control group.Analyze and compare the clinical efficacy of the two groups.Before and after 14 days of treatment,the levels of glial fibrillary acidic protein(GFAP),neuron specific enolase(NSE),serum myelin basic protein(MBP),and calcium-binding protein(S100B)were measured using enzyme-linked immunosorbent assay.The National Institutes of Health Stroke Scale(NIHSS)and the Modified Rankin Scale(mRS)were used to evaluate the neurological deficit and recovery,respectively.The occurrence of adverse reactions was also recorded.Results:The total effective rate of the observation group was significantly higher than that of the control group,and the scores of NSE,S100B,GFAP,MBP,NIHSS,and mRS were lower than those of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Butylphthalein combined with edaravone and camphor can improve the therapeutic effect of acute cerebral infarction,reduce the expression level of protein markers of neurological injury,promote the recovery of neurological function in patients,and have high safety.
万方数据
维普
